Cytokinetics and Amgen expand collaboration
Cytokinetics Inc. and Amgen Inc. said Wednesday that they are expanding their collaboration on a drug to treat heart failure in a deal worth at least $25 million. Full story
You Asked For It Trades
The FMHR crew have a play on the top four stocks lighting up the Twitter feed. Today, a look at Timken, Amgen, US Airways and IBM.
Amgen, Astellas agree to Japan market partnership
Biotech drug developer Amgen Inc. will partner with Japanese drugmaker Astellas Pharma Inc. to sell several potential Amgen treatments in Japan. Full story
Drugs from Amgen, others assessed by FDA as radiation treatments
(Reuters) - Drugs from Amgen Inc, Teva Pharmaceutical Industries and Sanofi that boost white blood cells are being evaluated by U.S. regulators as treatments for radiation exposure caused by a nuclear attack or accident. Full story
Amgen loses as top U.S. court backs class actions
WASHINGTON/NEW YORK (Reuters) - The U.S. Supreme Court made it easier on Wednesday for shareholders to bring class-action lawsuits, breaking a recent line of decisions that had made it harder to sue corporate defendants collectively and perhaps obtain greater recoveries. Full story
Amgen biosimilar push takes aim at blockbusters
NEW YORK (Reuters) - Amgen Inc said it expects generic versions of biotech drugs, known as biosimilars, to be a multibillion-dollar opportunity for the company and has targeted some of the industry's biggest sellers, including the main rivals for its own blockbuster rheumatoid arthritis drug Enbrel. Full story
Sponsored Links
Video
Cramer's Mad Dash: Biotech Stock Plays
Jim Cramer explains why Gilead Sciences and Amgen are the stocks to watch today.
advertisement | ad info
